How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
CAR-T Cell Immunotherapies for Cancer Market
- By Therapy Type: Autologous CAR-T Cell Therapy, Allogeneic CAR-T Cell Therapy
- By Target Antigen: CD19-targeted CAR-T, BCMA-targeted CAR-T, CD22-targeted CAR-T, CD20-targeted CAR-T, HER2-targeted CAR-T
- By Indication: B-cell Acute Lymphoblastic Leukemia (B-ALL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL)
- By Generation of CAR Construct: Second Generation CAR-T, Third Generation CAR-T, Fourth Generation CAR-T (TRUCKs)
- By Treatment Setting: Hospital Inpatient, Hospital Outpatient, Specialized Cancer Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Autologous CAR-T Cell Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the CAR-T Cell Immunotherapies for Cancer Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Kite Pharma (a Gilead Sciences company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bristol Myers Squibb (including Celgene)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Legend Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bluebird Bio
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Celyad Oncology
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Allogene Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Poseida Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Autolus Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sorrento Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Fate Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Immatics Biotechnologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Tmunity Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Caribou Biosciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Adaptimmune Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Autologous CAR-T Cell Therapy81.6
- Allogeneic CAR-T Cell Therapy18.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Kite Pharma (a Gilead Sciences company)19.4
- Novartis AG26.5
- Bristol Myers Squibb (including Celgene)6.2
- Legend Biotech7.5
- Bluebird Bio4.9
- Celyad Oncology7.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.9
- Europe22.2
- Asia Pacific20.7
- Latin America12.4
- Middle East and Africa10.8
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Kite Pharma (a Gilead Sciences company) | 74 | 77 | 93 | 95 | 81 | 84 | 84 |
| Novartis AG | 84 | 75 | 78 | 72 | 84 | 79 | 79 |
| Bristol Myers Squibb (including Celgene) | 87 | 78 | 81 | 75 | 77 | 85 | 81 |
| Legend Biotech | 73 | 62 | 65 | 60 | 63 | 62 | 64 |
| Bluebird Bio | 54 | 66 | 60 | 62 | 57 | 56 | 59 |
| Celyad Oncology | 56 | 59 | 71 | 47 | 63 | 66 | 60 |
| Allogene Therapeutics | 41 | 61 | 48 | 50 | 40 | 43 | 47 |
| Poseida Therapeutics | 44 | 38 | 41 | 53 | 51 | 45 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Kite Pharma (a Gilead Sciences company)
- Novartis AG
- Bristol Myers Squibb (including Celgene)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Kite Pharma (a Gilead Sciences company) | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Novartis AG | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Bristol Myers Squibb (including Celgene) | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Legend Biotech | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| Bluebird Bio | ◐ | − | ◐ | ◐ | ◐ | − |
| Celyad Oncology | ◐ | ◐ | ◐ | − | − | ◐ |
| Allogene Therapeutics | − | ◐ | ◐ | ◐ | − | ◐ |
| Poseida Therapeutics | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Contender3
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Therapy Type in North America, then scale across CAR-T Cell Immunotherapies for Cancer Market — a $225M beachhead inside a $3.55B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Autologous CAR-T Cell Therapy
Best fit — highest urgency & budget in Therapy Type.
Allogeneic CAR-T Cell Therapy
Strong fit — clear ROI and a fast path to value.
Enterprise buyers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Antigen & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win CAR-T Cell Immunotherapies for Cancer Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
CAR-T Cell Immunotherapies for Cancer Market is a durable-growth opportunity — $3.24B by 2033, compounding at 9.2%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.2% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Antigen optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
CAR-T Cell Immunotherapies for Cancer Market — a $3.60B market by 2033. Plan: grow share from 9.6% to 16.6%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.6% | 16.6% | On track |
| Revenue | $356M | $597M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 34.6% | 44.2% | At risk |
| Customer retention | 88.9% | 95.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Target Antigen capability
A defensible second engine — invest in Target Antigen to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Antigen
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $77M capacity & capability investment
- Greenlight bolt-on M&A in Target Antigen
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Sales deck · value proposition
Win the CAR-T Cell Immunotherapies for Cancer Market conversation — a $4.01B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your CAR-T Cell Immunotherapies for Cancer Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
CAR-T Cell Immunotherapies for Cancer Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →CAR T-Cell-Based Drug Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportCart-Based Ultrasound Device Market
Market size, share, segmentation and regional forecast.
$906M market · 2025 base year
View reportCart-based Color Ultrasonic Diagnostic Devices Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportCarrier Screening Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportCarrier RNA Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportCarprofen Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportNutraceuticals Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportAnimal Sourced Squalene Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportCarpal Tunnel Veterinary Splint Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportCarpal Tunnel Syndrome Treatment Market
Market size, share, segmentation and regional forecast.
$328M market · 2025 base year
View reportCarpal Braces for Dogs Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportCar Oxygen Concentrator Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy